Finance

Lists
006280:KRX
GC Biopharma Corp
â‚©129,100.00
-1.07%
(-1,400.00) 1D
Aug 31, 3:30:22 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 006280...
Open
â‚©128,900
High
â‚©129,300
Low
â‚©125,700
Mkt. cap
1.51T
Avg. vol.
35.30K
Volume
17.35K
Dividend
1.16%
Quarterly dividend
â‚©375
Ex-dividend date
Mar 30, 2026
52-wk high
â‚©183,800
52-wk low
â‚©105,900
EPS
-â‚©4,372
Shares outstanding
11.69M
No. of employees
2K
Open
â‚©128,900
High
â‚©129,300
Low
â‚©125,700
Mkt. cap
1.51T
Avg. vol.
35.30K
Volume
17.35K
Dividend
1.16%
Quarterly dividend
â‚©375
Ex-dividend date
Mar 30, 2026
52-wk high
â‚©183,800
52-wk low
â‚©105,900
EPS
-â‚©4,372
Shares outstanding
11.69M
No. of employees
2K
Profile
GC Biopharma also known as Green Cross Corporation is a biopharmaceutical company headquartered in Yongin, South Korea. Wikipedia
About GC Biopharma Corp
CEOEun Chul Huh | Il-sup Huh
Employees2.04K
FoundedOct 5, 1967
Headquarters-
SectorBiotechnology
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
609.49B
497.75B
435.53B
421.18B
Cost of goods sold
463.97B
357.85B
313.13B
312.00B
Cost of revenue
463.97B
357.85B
313.13B
312.00B
Research and development expenses
33.48B
44.81B
35.32B
38.34B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
77.09B
83.01B
70.35B
65.07B
Operating expense
116.30B
135.30B
110.67B
107.45B
Total operating expenses
580.27B
493.15B
423.80B
419.45B
Operating income
29.21B
4.60B
11.73B
1.73B
Other non operating income
13.04M
636.32M
-10.15B
-6.20B
EBT including unusual items
24.89B
-110.07B
28.59B
-1.60B
EBT excluding unusual items
21.52B
-4.39B
25.91B
-14.17B
Income tax expense
6.74B
-7.27B
8.45B
-2.65B
Effective tax rate
27.07%
6.61%
29.56%
165.54%
Other operating expenses
296.00M
306.00M
590.00M
308.00M
Net income
15.95B
-88.30B
20.47B
1.98B
Net profit margin
2.62%
-17.74%
4.70%
0.47%
Earnings per share
1.40K
-
1.79K
174.00
Interest and investment income
605.00M
623.00M
881.00M
418.00M
Interest expense
-12.76B
-13.40B
-13.27B
-11.50B
Net interest expenses
-12.15B
-12.77B
-12.39B
-11.08B
Depreciation and amortization charges
1.68B
2.17B
1.63B
1.22B
EBITDA
50.70B
24.79B
34.46B
22.90B
Gain or loss from assets sale
-268.00M
1.01B
-35.56B
38.60M
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps